Status:
COMPLETED
A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the absorption (the way the drug enters the body), metabolism (the way the drug is broken down in the body), and excretion (the way drug leaves the body) of...
Detailed Description
This study will be an open label (all volunteers and study staff know the identity of the assigned treatment), single dose, single center study to investigate the absorption, metabolism, and excretion...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) (weight \[kg\]/height \[m2\]) between 18 and 30 kg/m2
- Non-smoker
Exclusion
- Exposure to radiation for professional or medical reasons (except dental x-rays and x-rays of thorax and bone skeleton, excluding spinal column) in the past 12 months
- History of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01791231
Start Date
August 1 2007
End Date
October 1 2007
Last Update
June 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Merksem, Belgium